Our Services & Platforms
Drug discovery platforms, computational protein design, molecular simulation, and bioinformatics for pharmaceutical, biotech, and academic partners
CaliOmics — AI-Driven Multi-Omics Integration Engine
CaliOmics is our proprietary computational framework integrating genomics, transcriptomics, proteomics, metabolomics, and epigenomics with deep learning. Licensed to multiple pharma partners under multi-year agreements. Applied across oncology, immunology, and rare diseases to accelerate target identification.
The target discovery module combines CRISPR screening data, GWAS meta-analyses, and proprietary pathway models with confidence scoring to identify novel targets. Flexible deployment: fully licensed installations in partner data centers, cloud-hosted instances with data residency controls, and on-demand project analyses.
- Multi-omics data integration and harmonization across 5 molecular layers
- CRISPR screen integration with GWAS and eQTL meta-analysis
- Target druggability and ligandability scoring with structural modeling
- Disease-gene association mapping with tissue-specific expression weighting
- Competitive landscape and patent landscape analysis
- Custom model training on partner-proprietary datasets
- API integration with existing LIMS and data warehouse infrastructure
TherAlign — Precision Oncology Biomarker Discovery & Companion Diagnostics
TherAlign is our precision oncology biomarker discovery platform with companion diagnostic development capabilities. Built on tumor-normal whole-exome sequencing, RNA-seq, and quantitative proteomics with ML classification, TherAlign identifies prognostic and predictive biomarkers across solid tumors and hematological malignancies.
The platform has identified multiple candidate biomarkers, with panels in co-development with global oncology pharma partners. TherAlign supports companion diagnostic strategy from discovery through regulatory submission — including assay development, technical validation, and documentation.
- Prognostic and predictive biomarker identification with technical validation frameworks
- Patient stratification model development for clinical trial enrichment
- Companion diagnostic co-development and regulatory submission support (FDA/EMA)
- Tumor mutational burden, microsatellite instability, and PD-L1 expression analytics
- Longitudinal biomarker monitoring and ctDNA analysis
- Clinical trial enrichment strategy and retrospective cohort validation
- IP strategy support for biomarker patent filings and freedom-to-operate analysis
ImmunoScope — Immune Profiling for IO Development
ImmunoScope provides comprehensive immune profiling for IO drug development partnerships. The platform integrates TCR repertoire sequencing, tumor microenvironment single-cell transcriptomics, circulating immune cell flow cytometry, and cytokine multiplex profiling for a multidimensional view of patient immune response.
Currently in pilot programs with three major pharma partners developing next-gen checkpoint inhibitors, bispecific antibodies, and CAR-T therapies. ImmunoScope has identified novel predictive signatures for treatment response and immune-related adverse events. Delivered through project-based engagements and ongoing monitoring contracts for active trials, with fast turnaround for urgent biomarker readouts.
- TCR and BCR repertoire diversity and clonality analysis
- Tumor microenvironment deconvolution via single-cell and spatial transcriptomics
- Predictive biomarker discovery for immune-related adverse events (irAEs)
- Combination therapy rationale and synergy prediction
- Real-time clinical trial biomarker monitoring with rapid turnaround
- Integration with partner clinical data management systems (Medidata, Veeva)
- Regulatory-grade documentation for biomarker qualification packages
PathwayPredict & ClinicalConnect — AI-Driven MOA & RWE Analytics
PathwayPredict and ClinicalConnect form our regulatory strategy and clinical optimization suite. PathwayPredict uses systems pharmacology modeling and network analysis to deconvolute drug MOAs, predict off-target liabilities, and identify indication expansion opportunities. In early access with leading biopharma companies, with strong accuracy in off-target prediction.
ClinicalConnect integrates RWE from EHR, claims, disease registries, and curated literature to optimize trial design, refine patient stratification, and strengthen regulatory submission packages. Our regulatory team provides end-to-end submission strategy for FDA and EMA filings, including biomarker qualification packages, statistical analysis plans, and integrated summaries of efficacy and safety.
- Drug-target interaction mapping and pathway network analysis
- Off-target effect prediction with strong predictive capability
- Indication expansion and drug repurposing opportunity assessment
- Real-world evidence integration from EHR, claims, and registry data
- Clinical trial optimization via synthetic control arm generation
- Regulatory submission strategy support (FDA, EMA)
- Biomarker qualification package and statistical analysis plan development
Engagement Models & Client Segments
We offer engagement models tailored to each partner's scale, therapeutic focus, and regulatory needs. From multi-year co-development agreements to on-demand project analyses, our structures align incentives and maximize ROI.
Platform Licensing: Multi-year enterprise licenses for CaliOmics, TherAlign, or ImmunoScope with dedicated compute, custom model training, and ongoing support. Includes quarterly platform upgrades and partner-specific feature development.
Project-Based Analytical Services: Milestone-based engagements for target discovery, biomarker validation, or clinical trial analytics. Timelines range from focused pilots for target identification to extended engagements for biomarker validation and precision medicine programs.
Strategic Co-Development: Deep partnerships with shared IP, joint steering committees, and success-based milestone payments tied to therapeutic validation, biomarker approvals, or development milestones. Current agreements include our TherAlign precision medicine program and ImmunoScope IO monitoring platform.
Technical Capabilities: Whole-genome/exome sequencing, bulk and single-cell RNA-seq, ATAC-seq, ChIP-seq, quantitative proteomics and metabolomics (LC-MS/MS, DIA), epigenomic profiling, spatial transcriptomics, AI/ML model development, computational protein design, molecular dynamics simulation, systems pharmacology, RWE analytics, and FDA/EMA regulatory submission documentation.